Ortho’s Ortho-Cyclen oral contraceptive
Formulation containing .035 mg ethinyl estradiol/0.25 mg norgestimate is now available at pharmacies at an average retail price of $20 -$21, Ortho Pharmaceutical announces Oct. 14. The monophasic product, originally approved Dec. 29, 1989, is the first OC in the U.S. with the synthetic progesterone norgestimate. Ortho was barred from marketing Ortho-Cyclen in the U.S. until a Sept. 24 court ruling vacated an injunction granted to American Home Products. AHP had originally filed a patent infringement suit against Ortho-Cyclen in early 1990 ("The Pink Sheet" March 5, 1990, T&G-10).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth